Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HQK-1001 in Beta Thalassemia Intermedia
NCT00790127Phase 2Completed
- Sponsor
- HemaQuest Pharmaceuticals, Inc.
- Start
- Mar 2009
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in beta-thalassemia intermedia and hemoglobin E beta thalassemia (HbE/β-thal) comparing Placebo with HQK-1001 (2 arms). Primary endpoint: Safety and Tolerability at 168 days. Started Mar 2009; status: completed.
02
Drugs
sodium 2,2-dimethylbutyrate
03
Conditions
beta-thalassemia intermediahemoglobin E beta thalassemia (HbE/β-thal)
Beyond the preview
Go deeper on NCT00790127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00790127.